Literature DB >> 10064070

Induction of interferon-gamma production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation.

J Yang1, T L Murphy, W Ouyang, K M Murphy.   

Abstract

IFN-gamma produced by CD4+ T helper 1 (Th1) cells promotes protection against intracellular pathogens. Antigen activation of Th1 cells is an important mode of IFN-gamma induction, but here we analyze a second, antigen-nonspecific pathway capable of inducing full IFN-gamma transcription. IL-12 or IL-18 alone do not induce IFN-gamma mRNA, and only modestly augment antigen-induced IFN-gamma mRNA from Th1 cells. However, IL-12 and IL-18 together fully induce IFN-gamma transcription independently of TCR-activated signals, by a mechanism that does not simply involve Stat4 and NF-kappaB activation, but requires additional protein synthesis. Cyclosporin A inhibits TCR-induced IFN-gamma production, but not IL-12/IL-18-induced IFN-gamma production, biochemically discriminating between these pathways. These results suggest that the two pathways induce IFN-gamma production through functionally segregated but spatially overlapping cis-acting elements, similar to other genes under the control of two or more promoters.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064070     DOI: 10.1002/(SICI)1521-4141(199902)29:02<548::AID-IMMU548>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  60 in total

Review 1.  Molecular mechanisms in T helper phenotype development.

Authors:  J D Farrar; S H Ranganath; K M Murphy
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Genetic regulation of acquired immune responses to antigens of Mycobacterium tuberculosis: a study of twins in West Africa.

Authors:  A Jepson; A Fowler; W Banya; M Singh; S Bennett; H Whittle; A V Hill
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

3.  GADD45beta/GADD45gamma and MEKK4 comprise a genetic pathway mediating STAT4-independent IFNgamma production in T cells.

Authors:  Hongbo Chi; Binfeng Lu; Mutsuhiro Takekawa; Roger J Davis; Richard A Flavell
Journal:  EMBO J       Date:  2004-03-25       Impact factor: 11.598

4.  Modular utilization of distal cis-regulatory elements controls Ifng gene expression in T cells activated by distinct stimuli.

Authors:  Anand Balasubramani; Yoichiro Shibata; Gregory E Crawford; Albert S Baldwin; Robin D Hatton; Casey T Weaver
Journal:  Immunity       Date:  2010-07-23       Impact factor: 31.745

Review 5.  Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases.

Authors:  Mei Lan Chen; Mark S Sundrud
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

6.  T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-gamma expression.

Authors:  Meixiao Long; Aaron M Slaiby; Adam T Hagymasi; Marianne A Mihalyo; Alexander C Lichtler; Steven L Reiner; Adam J Adler
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

Review 7.  How diverse--CD4 effector T cells and their functions.

Authors:  Yisong Y Wan; Richard A Flavell
Journal:  J Mol Cell Biol       Date:  2009-05-28       Impact factor: 6.216

8.  IFN-alpha is not sufficient to drive Th1 development due to lack of stable T-bet expression.

Authors:  Hilario J Ramos; Ann M Davis; Thaddeus C George; J David Farrar
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

9.  IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells.

Authors:  Qianting Yang; Gang Li; Yibei Zhu; Lin Liu; Elizabeth Chen; Hēth Turnquist; Xueguang Zhang; Olivera J Finn; Xinchun Chen; Binfeng Lu
Journal:  Eur J Immunol       Date:  2011-10-13       Impact factor: 5.532

10.  The bradykinin B2 receptor in the early immune response against Listeria infection.

Authors:  Wendy E Kaman; Arthur F W M Wolterink; Michael Bader; Linda C L Boele; Desiree van der Kleij
Journal:  Med Microbiol Immunol       Date:  2008-09-23       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.